Compile Data Set for Download or QSAR
Report error Found 29 Enz. Inhib. hit(s) with all data for entry = 10165
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518146(US11111240, Example 23)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518147(US11111240, Example 24)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518148(US11111240, Example 25)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518154(US11111240, Example 26)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518155(US11111240, Example 27)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518124(US11111240, Example 2)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518124(US11111240, Example 2)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518126(US11111240, Example 4)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518129(US11111240, Example 6)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518131(US11111240, Example 8)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518133(US11111240, Example 10)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM50503243(CHEMBL4560565 | US11111240, Example 12)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM50503243(CHEMBL4560565 | US11111240, Example 12)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518137(US11111240, Example 14)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518139(US11111240, Example 16)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518143(US11111240, Example 20)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518141(US11111240, Example 18)
Affinity DataIC50: 100nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518134(US11111240, Example 11)
Affinity DataIC50: 500nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518138(US11111240, Example 15)
Affinity DataIC50: 500nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518125(US11111240, Example 3)
Affinity DataIC50: 500nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518130(US11111240, Example 7)
Affinity DataIC50: 500nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518132(US11111240, Example 9)
Affinity DataIC50: 1.00E+3nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518136(US11111240, Example 13)
Affinity DataIC50: 1.00E+3nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518142(US11111240, Example 19)
Affinity DataIC50: 1.00E+3nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518128(US11111240, Example 5)
Affinity DataIC50: 1.00E+3nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518145(US11111240, Example 22)
Affinity DataIC50: 1.00E+3nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518123(US11111240, Example 1)
Affinity DataIC50: 1.00E+4nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518140(US11111240, Example 17)
Affinity DataIC50: 1.00E+4nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chai Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM518144(US11111240, Example 21)
Affinity DataIC50: 1.00E+4nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
US Patent